Abstract
Somatostatins are neuropeptides that exert a downregulatory effect on various physiological processes.
Somatostatin analogues are used in the imaging and management of various tumour types. Their role in thyroid cancer has not as yet been fully elucidated.
A systematic review of the literature using the keywords thyroid, cancer and somatostatin revealed 263 references.
This paper summarizes the current knowledge of the role of somatostatins in thyroid cancer and assesses their future potential.
See also Somatostatin in oncology, the overlooked evidences.